In the biotech field, most people perceive risk as whether a drug will succeed or fail in a clinical study. But as biotech companies mature, the risks they need to manage grow in complexity, particularly as companies become increasingly reliant on a complex network of external relationships. Hear from RSM’s Life Sciences Senior Analyst Steve Kemler about the types of risks biotech companies face and how to manage them, as well as why biotech companies should develop a risk assessment framework.